Skip to main content

NANONEUROPROTECCION TERMO-MOLECULAR VECTORIZADA EN LA ISQUEMIA CEREBRAL.

SAF2014-56336-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke

  • Silva Candal, Andrés da
  • Pérez Díaz, Amparo
  • Santamaría, María
  • Rodríguez‐Yáñez, Manuel
  • Ardá, Ana
  • Pérez Mato, María
  • Correa Paz, Clara
  • Iglesias Rey, Ramón
  • Brea Floriani, José Manuel
  • Azuaje Guerrero, Jhonny Alberto
  • Sotelo Pérez, Eddy
  • Sobrino, Tomás
  • Loza García, María Isabel
  • Castillo, José
  • Campos Pérez, Francisco
Objective: Blood/brain-glutamate grabbing is an emerging concept in the treatment of acute ischemic stroke, where essentially the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. Aiming to demonstrate the clinical efficacy of blood glutamate grabbers in patients with stroke, in this study, we resorted to a drug-repositioning strategy for the discovery of new glutamate-grabbing drugs. Methods: The glutamate-grabbing ability of 1,120 compounds (90% of which were drugs approved by the US Food and Drug Administration) was evaluated during an in vitro high-throughput screening campaign. Subsequently, the protective efficacy of the selected drugs was probed in an ischemic animal model and finally tested in stroke patients. Results: Riboflavin (vitamin B2 ) was identified as the main hit compound. In ischemic animal models treated with riboflavin (1mg/kg), it was confirmed that blood glutamate reduction was associated with a significant reduction of infarct size. These results led to a randomized, double-blind, phase IIb clinical trial with patients with stroke. Fifty patients were randomized to 1 of the 2 study arms: the control group (placebo) and the experimental group (20mg of riboflavin [vitamin B2 Streuli@ ). Decrease in glutamate concentration was significantly greater (p < 0.029) in the treated group. Comparative analysis of the percentage improvement on the National Institutes of Health Stroke Scale score at discharge was slightly higher in the riboflavin-treated group than in the placebo group (33.7 ± 43.7 vs 48.9 ± 42.4%, p = 0.050). Interpretation: This translational study represents the first human demonstration of the efficacy of blood glutamate grabbers in the treatment of patients with stroke, paving the way for the development of a promising novel protective therapy
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Blood glutamate EAAT2-cell grabbing therapy in cerebral ischemia

  • Pérez Mato, María
  • Iglesias Rey, Ramón
  • Vieites Prado, Alba
  • Dopico López, Antonio
  • Argibay González, Bárbara
  • Fernández Susavila, Héctor
  • Silva Candal, Andrés da
  • Pérez Díaz, Amparo
  • Correa Paz, Clara
  • Günther, Anne
  • Ávila Gómez, Paulo
  • Loza García, María Isabel
  • Baumann, Arnd
  • Castillo Sánchez, José Antonio
  • Sobrino Moreiras, Tomás
  • Campos Pérez, Francisco
Background Excitatory amino acid transporter 2 (EAAT2) plays a pivotal role in glutamate clearance in the adult brain, thereby preventing excitotoxic effects. Considering the high efficacy of EAAT2 for glutamate uptake, we hypothesized that the expression of this transporter in mesenchymal stem cells (MSCs) for systemic administration could yield a cell-based glutamate-grabbing therapy, combining the intrinsic properties of these cells with excitotoxic protection. Methods To address this hypothesis, EAAT2-encoding cDNA was introduced into MSCs and human embryonic kidney 293 cells (HEK cells) as the control cell line. EAAT2 expression and functionality were evaluated by in vitro assays. Blood glutamate-grabbing activity was tested in healthy and ischemic rat models treated with 3 × 106 and 9 × 106 cells/animal. Findings The expression of EAAT2 in both cell types conferred the expected glutamate-grabbing activity in in vitro and in vivo studies. The functional improvement observed in ischemic rats treated with EAAT2–HEK at low dose, confirmed that this effect was indeed mediated by the glutamate-grabbing activity associated with EAAT2 functionality. Unexpectedly, both cell doses of non-transfected MSCs induced higher protection than transfected EAAT2–MSCs by another mechanism independent of the glutamate-grabbing capacity. Interpretation Although the transfection procedure most likely interferes with some of the intrinsic protective mechanisms of mesenchymal cells, the results show that the induced expression of EAAT2 in cells represents a novel alternative to mitigate the excitotoxic effects of glutamate and paves the way to combine this strategy with current cell therapies for cerebral ischemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of High Serum Levels of Growth Factors with Good Outcome in Ischemic Stroke, a Multicenter Study

  • Sobrino, Tomás|||0000-0002-9760-8690
  • Rodríguez-Yáñez, Manuel
  • Campos, Francisco|||0000-0001-8665-1039
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Pérez de la Ossa, Natalia|||0000-0002-6063-211X
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Serena, Joaquín|||0000-0002-4478-7744
  • Lago, Aida
  • Díez-Tejedor, Exuperio
  • Castillo, José
The main objective of this research work was to study the association of serum levels of growth factors (GF) and SDF-1α with the functional outcome and reduction of lesion volume in ischemic stroke patients. In this multicenter study, 552 patients with non-lacunar stroke (male, 62.1%; mean age, 68.2 ± 11.4) were included within 24 h from symptom onset. The main outcome variable was good functional outcome (modified Rankin Scale [mRS] ≤ 2) at 12 months. Secondary outcome variable was infarct volume (in mL) after 6 ± 3 months. Serum levels of VEGF, Ang-1, G-CSF, BDNF, and SDF-1α were measured by ELISA at admission, 7 ± 1 days, at 3 ± 1 months, and 12 ± 3 months. Except for BDNF, all GF and SDF-1α serum levels showed a peak value at day 7 and remained elevated during the first 3 months (all p < 0.01). High serum levels at day 7 of VEGF (OR, 19.3), Ang-1 (OR, 14.7), G-CSF (OR, 9.6), and SDF-1α (OR, 28.5) were independently associated with good outcome at 12 months (all p < 0.0001). On the other hand, serum levels of VEGF (B, - 21.4), G-CSF (B, - 14.0), Ang-1 (B, - 13.3), and SDF-1α (B, - 44.6) measured at day 7 were independently associated with lesion volume at 6 months (p < 0.01). In summary, high serum levels of VEGF, Ang-1, G-CSF, and SDF-1α at day 7 and 3 months after ischemic stroke are associated with good functional outcome and smaller residual lesion at 1 year of follow-up.